Author

Anthony Buisson

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY
LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY

Anthony Buisson  et al.

DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE
DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE

DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE
DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE

Anthony Buisson  et al.

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY

Anthony Buisson  et al.

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

Anthony Buisson  et al.

Navigating Experience and Possibilities with Subcutaneous Infliximab as a Biobetter in IBD (Celltrion Healthcare)
Navigating Experience and Possibilities with Subcutaneous Infliximab as a Biobetter in IBD (Celltrion Healthcare)

Anthony Buisson  et al.

TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS
TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS

Anthony Buisson  et al.

DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION
DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION

Anthony Buisson  et al.

INTERACTION BETWEEN CHITINASE 3-LIKE 1 (CHI3L1) AND BACTERIAL PROTEIN CHIA: A DECISIVE STEP FOR CROHN’S DISEASE-ASSOCIATED ADHERENT AND INVASIVE E. COLI TO ENTER WITHIN HUMAN MACROPHAGES
INTERACTION BETWEEN CHITINASE 3-LIKE 1 (CHI3L1) AND BACTERIAL PROTEIN CHIA: A DECISIVE STEP FOR CROHN’S DISEASE-ASSOCIATED ADHERENT AND INVASIVE E. COLI TO ENTER WITHIN HUMAN MACROPHAGES

Anthony Buisson  et al.

COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE

Anthony Buisson  et al.

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID
EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

Anthony Buisson  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

Anthony Buisson  et al.

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT

Anthony Buisson  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

Anthony Buisson  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Anthony Buisson  et al.

Item 1 - 16 / 16
1